Completed PHASE1 INTERVENTIONAL 4-arm NCT05571787

HMPL-523 Food Effect and Proton Pump Inhibitor Study

A Phase 1, Open-label, 4-period, Randomized 6-sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers

Sponsor: Hutchmed

Conditions Relapsed or Refractory Lymphoma

Interventions HMPL-523 Rabeprazole

Updated 4 times since 2022 Last updated: Feb 22, 2023 Started: Jul 13, 2022 Primary completion: Sep 22, 2022 Completion: Sep 22, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Relapsed or Refractory Lymphoma, this trial is completed. The trial is conducted by Hutchmed and has accumulated 4 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2023 — Jul 2024 [monthly]

Completed PHASE1
Nov 2022 — Mar 2023 [monthly]

Completed PHASE1

First recorded

Jul 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hutchmed

Data source: Hutchmed

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Austin, United States